Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for ARDX

Stock NameArdelyx Inc
TickerARDX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS0396971071
LEI549300F542QR4SXHCY32

Show aggregate ARDX holdings

News associated with ARDX

Implied XBI Analyst Target Price: $142
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-15 07:18:21
Ardelyx (NASDAQ:ARDX) CEO Michael Raab Sells 45,687 Shares of Stock
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) CEO Michael Raab sold 45,687 shares of Ardelyx stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $5.93, for a total value of $270,923.91. Following the transaction, the chief executive officer owned 1,502,250 shares in the company, valued at $8,908,342.50. […] - 2025-08-26 05:24:52
Stock Traders Purchase Large Volume of Call Options on Ardelyx (NASDAQ:ARDX)
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors bought 10,249 call options on the company. Thisisanincreaseofapproximately439% compared to the typical daily volume of 1,902 call options. Insider Activity In other Ardelyx news, CEO Michael Raab sold 46,817 shares of the stock in a […] - 2025-08-14 02:19:05
HC Wainwright Estimates Ardelyx’s Q3 Earnings (NASDAQ:ARDX)
Ardelyx, Inc. (NASDAQ:ARDX – Free Report) – Equities researchers at HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for shares of Ardelyx in a note issued to investors on Tuesday, August 5th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will post earnings of ($0.07) per share for the […] - 2025-08-08 02:55:07
Mackenzie Financial Corp Grows Stock Position in Ardelyx, Inc. (NASDAQ:ARDX)
Mackenzie Financial Corp boosted its position in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 6.4% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 149,158 shares of the biopharmaceutical company’s stock after purchasing an additional 9,025 shares during the period. Mackenzie Financial Corp’s holdings in Ardelyx were worth $732,000 as of its most recent […] - 2025-08-07 05:04:52
Ardelyx (NASDAQ:ARDX) Shares Gap Up After Better-Than-Expected Earnings
Shares of Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed at $4.39, but opened at $5.07. Ardelyx shares last traded at $5.06, with a volume of 3,144,528 shares traded. The biopharmaceutical company reported ($0.08) earnings per […] - 2025-08-07 02:13:02
Ardelyx (NASDAQ:ARDX) versus Esperion Therapeutics (NASDAQ:ESPR) Head to Head Review
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) and Ardelyx (NASDAQ:ARDX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Institutional and Insider Ownership 47.4% of Esperion Therapeutics […] - 2025-08-01 04:30:46
Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 424,718 Ardelyx, Inc. (NASDAQ:ARDX)
Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 424,718 shares of the biopharmaceutical company’s stock, valued at approximately $2,085,000. Universal Beteiligungs und Servicegesellschaft mbH owned […] - 2025-07-31 05:14:48
Brokerages Set Ardelyx, Inc. (NASDAQ:ARDX) PT at $10.89
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) has earned an average rating of “Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the […] - 2025-07-30 04:24:53
Cwm LLC Buys 78,063 Shares of Ardelyx, Inc. (NASDAQ:ARDX)
Cwm LLC lifted its stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 4,554.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,777 shares of the biopharmaceutical company’s stock after buying an additional 78,063 shares during the quarter. Cwm LLC’s holdings in Ardelyx were […] - 2025-07-25 05:09:08
Ardelyx, Inc. (NASDAQ:ARDX) Given Consensus Recommendation of “Buy” by Brokerages
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) has earned an average recommendation of “Buy” from the ten brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The […] - 2025-06-30 02:46:46
HC Wainwright Forecasts Ardelyx’s Q2 Earnings (NASDAQ:ARDX)
Ardelyx, Inc. (NASDAQ:ARDX – Free Report) – HC Wainwright issued their Q2 2025 earnings per share estimates for Ardelyx in a research note issued to investors on Wednesday, June 18th. HC Wainwright analyst M. Caufield anticipates that the biopharmaceutical company will post earnings per share of ($0.14) for the quarter. HC Wainwright has a “Buy” […] - 2025-06-24 02:24:51
World Equity Group Inc. Acquires New Shares in Ardelyx, Inc. (NASDAQ:ARDX)
World Equity Group Inc. bought a new position in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 17,400 shares of the biopharmaceutical company’s stock, valued at approximately $85,000. Other large investors have also bought and sold […] - 2025-06-23 05:36:49
SG Americas Securities LLC Buys 111,457 Shares of Ardelyx, Inc. (NASDAQ:ARDX)
SG Americas Securities LLC boosted its stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 203.1% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 166,343 shares of the biopharmaceutical company’s stock after buying an additional 111,457 shares during the quarter. SG Americas Securities LLC’s holdings in Ardelyx were worth $817,000 as of its […] - 2025-06-20 05:12:54
Ardelyx (NASDAQ:ARDX) Now Covered by HC Wainwright
Investment analysts at HC Wainwright initiated coverage on shares of Ardelyx (NASDAQ:ARDX – Get Free Report) in a research note issued on Wednesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 177.01% from the stock’s previous […] - 2025-06-20 02:15:21
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Recommendation of “Moderate Buy” by Analysts
Shares of Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on […] - 2025-06-05 02:48:52
Mackenzie Financial Corp Purchases 101,841 Shares of Ardelyx, Inc. (NASDAQ:ARDX)
Mackenzie Financial Corp raised its position in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 266.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 140,133 shares of the biopharmaceutical company’s stock after acquiring an additional 101,841 shares during the period. Mackenzie Financial Corp’s holdings in Ardelyx were worth $710,000 as of its most recent […] - 2025-06-02 05:49:04
Two Sigma Advisers LP Increases Position in Ardelyx, Inc. (NASDAQ:ARDX)
Two Sigma Advisers LP grew its stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 206.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 593,700 shares of the biopharmaceutical company’s stock after acquiring an additional 400,100 shares during the quarter. Two Sigma Advisers […] - 2025-05-28 06:23:01
ProShare Advisors LLC Acquires 19,643 Shares of Ardelyx, Inc. (NASDAQ:ARDX)
ProShare Advisors LLC lifted its holdings in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 34.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,469 shares of the biopharmaceutical company’s stock after buying an additional 19,643 shares during the period. ProShare […] - 2025-05-28 04:54:54
Ardelyx, Inc. (NASDAQ:ARDX) Shares Purchased by Two Sigma Investments LP
Two Sigma Investments LP grew its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 16.0% in the 4th quarter, Holdings Channel reports. The fund owned 1,141,777 shares of the biopharmaceutical company’s stock after acquiring an additional 157,416 shares during the period. Two Sigma Investments LP’s holdings in Ardelyx were worth $5,789,000 as […] - 2025-05-27 05:29:06
Analysts Set Ardelyx, Inc. (NASDAQ:ARDX) Target Price at $10.39
Shares of Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating […] - 2025-05-14 02:34:50
126,530 Shares in Ardelyx, Inc. (NASDAQ:ARDX) Acquired by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL purchased a new stake in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 126,530 shares of the biopharmaceutical company’s stock, valued at approximately $642,000. Tudor Investment Corp ET AL owned about […] - 2025-05-08 06:12:50
First Trust Advisors LP Sells 305,383 Shares of Ardelyx, Inc. (NASDAQ:ARDX)
First Trust Advisors LP lowered its stake in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 53.2% during the fourth quarter, Holdings Channel reports. The fund owned 268,924 shares of the biopharmaceutical company’s stock after selling 305,383 shares during the period. First Trust Advisors LP’s holdings in Ardelyx were worth $1,363,000 at the end […] - 2025-05-07 05:15:07
Ardelyx (NASDAQ:ARDX) Stock Price Down 8.4% Following Insider Selling
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) shares dropped 8.4% during trading on Monday after an insider sold shares in the company. The stock traded as low as $3.89 and last traded at $3.79. Approximately 3,550,524 shares were traded during trading, a decline of 18% from the average daily volume of 4,347,468 shares. The stock […] - 2025-05-07 02:23:00
Raymond James Financial Inc. Takes Position in Ardelyx, Inc. (NASDAQ:ARDX)
Raymond James Financial Inc. bought a new stake in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) in the 4th quarter, HoldingsChannel.com reports. The firm bought 183,490 shares of the biopharmaceutical company’s stock, valued at approximately $930,000. Several other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings […] - 2025-05-06 04:36:46
Ardelyx (NASDAQ:ARDX) Lowered to “Sell” Rating by StockNews.com
StockNews.com cut shares of Ardelyx (NASDAQ:ARDX – Free Report) from a hold rating to a sell rating in a report released on Monday. Other analysts have also recently issued research reports about the stock. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $11.00 price target on shares of Ardelyx in a research note […] - 2025-05-06 02:56:44
Wedbush Estimates Ardelyx’s Q4 Earnings (NASDAQ:ARDX)
Ardelyx, Inc. (NASDAQ:ARDX – Free Report) – Equities research analysts at Wedbush boosted their Q4 2025 earnings estimates for Ardelyx in a research report issued on Friday, May 2nd. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of $0.01 for the quarter, up from their previous estimate of […] - 2025-05-05 04:24:50
Barclays PLC Sells 14,671 Shares of Ardelyx, Inc. (NASDAQ:ARDX)
Barclays PLC reduced its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 532,654 shares of the biopharmaceutical company’s stock after selling 14,671 shares during the period. Barclays PLC’s holdings […] - 2025-05-01 05:12:53
LPL Financial LLC Has $704,000 Position in Ardelyx, Inc. (NASDAQ:ARDX)
LPL Financial LLC lessened its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 29.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 138,804 shares of the biopharmaceutical company’s stock after selling 58,562 shares during the period. LPL Financial LLC’s holdings in Ardelyx were worth […] - 2025-04-23 04:18:48
CreativeOne Wealth LLC Takes $274,000 Position in Ardelyx, Inc. (NASDAQ:ARDX)
CreativeOne Wealth LLC purchased a new position in Ardelyx, Inc. (NASDAQ:ARDX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 53,993 shares of the biopharmaceutical company’s stock, valued at approximately $274,000. Other institutional investors and hedge funds have also […] - 2025-04-21 05:13:01

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ARDX holdings

DateNumber of ARDX Shares HeldBase Market Value of ARDX SharesLocal Market Value of ARDX SharesChange in ARDX Shares HeldChange in ARDX Base ValueCurrent Price per ARDX Share HeldPrevious Price per ARDX Share Held
2025-11-11 (Tuesday)154,786USD 948,838ARDX holding increased by 74297USD 948,8380USD 74,297 USD 6.13 USD 5.65
2025-11-10 (Monday)154,786ARDX holding increased by 398USD 874,541ARDX holding increased by 11512USD 874,541398USD 11,512 USD 5.65 USD 5.59
2025-11-07 (Friday)154,388USD 863,029ARDX holding decreased by -9263USD 863,0290USD -9,263 USD 5.59 USD 5.65
2025-11-06 (Thursday)154,388ARDX holding increased by 398USD 872,292ARDX holding decreased by -43949USD 872,292398USD -43,949 USD 5.65 USD 5.95
2025-11-05 (Wednesday)153,990USD 916,241ARDX holding increased by 53897USD 916,2410USD 53,897 USD 5.95 USD 5.6
2025-11-04 (Tuesday)153,990ARDX holding increased by 400USD 862,344ARDX holding decreased by -46909USD 862,344400USD -46,909 USD 5.6 USD 5.92
2025-11-03 (Monday)153,590USD 909,253ARDX holding decreased by -21502USD 909,2530USD -21,502 USD 5.92 USD 6.06
2025-10-31 (Friday)153,590USD 930,755ARDX holding increased by 161269USD 930,7550USD 161,269 USD 6.06 USD 5.01
2025-10-30 (Thursday)153,590ARDX holding increased by 2005USD 769,486ARDX holding increased by 17624USD 769,4862,005USD 17,624 USD 5.01 USD 4.96
2025-10-29 (Wednesday)151,585ARDX holding increased by 802USD 751,862ARDX holding decreased by -18639USD 751,862802USD -18,639 USD 4.96 USD 5.11
2025-10-28 (Tuesday)150,783USD 770,501ARDX holding increased by 1508USD 770,5010USD 1,508 USD 5.11 USD 5.1
2025-10-27 (Monday)150,783USD 768,993ARDX holding increased by 9047USD 768,9930USD 9,047 USD 5.1 USD 5.04
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ARDX by Blackrock for IE00BYXG2H39

Show aggregate share trades of ARDX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY3985.7805.630 5.645USD 2,247 5.00
2025-11-06BUY3985.9905.640 5.675USD 2,259 4.99
2025-11-04BUY4006.0405.590 5.635USD 2,254 4.98
2025-10-30BUY2,0055.1054.920 4.939USD 9,902 4.97
2025-10-29BUY8024.9605.110 5.095USD 4,086 4.97
2025-10-22SELL-1,5965.1505.320 5.303USD -8,464 4.97 Loss of -536 on sale
2025-10-20BUY7985.1005.180 5.172USD 4,127 4.96
2025-10-17BUY1,9925.0305.060 5.057USD 10,074 4.96
2025-10-15BUY3,1765.1305.160 5.157USD 16,379 4.96
2025-10-03BUY2,8075.2605.350 5.341USD 14,992 4.96
2025-10-02BUY4005.2505.355 5.345USD 2,138 4.96
2025-09-30BUY8005.5105.635 5.623USD 4,498 4.95
2025-09-26BUY8005.5406.035 5.985USD 4,788 4.95
2025-09-25BUY8005.9606.140 6.122USD 4,898 4.94
2025-09-24SELL-6,7346.1506.205 6.199USD -41,747 4.93 Loss of -8,518 on sale
2025-09-18BUY4206.4206.425 6.425USD 2,698 4.93
2025-09-17BUY1,2636.1906.490 6.460USD 8,159 4.92
2025-08-20SELL-1,6765.9905.990 5.990USD -10,039 4.89 Loss of -1,849 on sale
2025-07-30BUY1,6724.3404.470 4.457USD 7,452 4.87
2025-07-17SELL-8364.5204.690 4.673USD -3,907 4.90 Profit of 192 on sale
2025-07-11SELL-3,3604.4904.675 4.657USD -15,646 4.91 Profit of 859 on sale
2025-07-07BUY1,2604.3504.370 4.368USD 5,504 4.92
2025-07-02BUY23,1554.1904.340 4.325USD 100,145 4.93
2025-06-20BUY7,4553.5603.710 3.695USD 27,546 4.94
2025-06-11BUY7963.7003.790 3.781USD 3,010 5.01
2025-06-10BUY7963.7403.880 3.866USD 3,077 5.02
2025-06-04SELL-3983.6903.955 3.928USD -1,564 5.06 Profit of 451 on sale
2025-04-23BUY3944.8505.070 5.048USD 1,989 5.34
2025-04-10SELL-3,1524.2504.390 4.376USD -13,793 5.41 Profit of 3,272 on sale
2025-04-08SELL-3944.3304.730 4.690USD -1,848 5.44 Profit of 294 on sale
2025-04-07SELL-3944.4504.600 4.585USD -1,806 5.45 Profit of 340 on sale
2025-04-04SELL-1,9754.5504.705 4.689USD -9,262 5.46 Profit of 1,520 on sale
2025-04-01BUY1,6324.7904.950 4.934USD 8,052 5.47
2025-03-31SELL-1,1884.9105.000 4.991USD -5,929 5.48 Profit of 582 on sale
2025-03-21BUY5,8855.1305.495 5.458USD 32,123 5.51
2025-03-14SELL-6,0485.4705.520 5.515USD -33,355 5.52 Profit of 10 on sale
2025-03-07SELL-7545.3005.475 5.457USD -4,115 5.53 Profit of 51 on sale
2025-03-04SELL-3785.4105.460 5.455USD -2,062 5.53 Profit of 29 on sale
2025-02-25BUY7565.1805.180 5.180USD 3,916 5.56
2025-02-19SELL-3756.3606.550 6.531USD -2,449 5.56 Loss of -364 on sale
2025-02-13BUY1,1255.6605.690 5.687USD 6,398 5.53
2025-02-12BUY3755.4505.580 5.567USD 2,088 5.53
2025-02-11BUY1,5005.5205.570 5.565USD 8,348 5.53
2024-12-30SELL-11,5005.2505.265 5.263USD -60,530 5.57 Profit of 3,556 on sale
2024-11-18SELL-6,0904.9605.060 5.050USD -30,754 5.80 Profit of 4,556 on sale
2024-11-08SELL-4045.0705.870 5.790USD -2,339 5.94 Profit of 59 on sale
2024-10-21SELL-4075.8805.890 5.889USD -2,397 0.00 Loss of -2,397 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ARDX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19243,5080910,71126.7%
2025-09-18163,03101,218,55513.4%
2025-09-17192,4177201,041,65118.5%
2025-09-16343,49101,238,00627.7%
2025-09-15380,88701,269,37330.0%
2025-09-12277,1720972,85528.5%
2025-09-11424,04101,606,78126.4%
2025-09-10296,2305,6491,113,03226.6%
2025-09-09493,0525,2911,532,35832.2%
2025-09-08299,64011,5501,323,25722.6%
2025-09-05307,2192131,359,35922.6%
2025-09-04606,21936,3482,075,19529.2%
2025-09-03442,7221501,420,81331.2%
2025-09-02318,19201,214,56926.2%
2025-08-29309,4459,669919,46033.7%
2025-08-28259,2928,8971,103,31823.5%
2025-08-27230,2390948,60124.3%
2025-08-26184,4950671,53927.5%
2025-08-25397,81701,470,03527.1%
2025-08-22478,3835,4891,695,41028.2%
2025-08-21675,006362,1751,442,46446.8%
2025-08-20583,35202,375,09824.6%
2025-08-19423,3901,3282,214,57519.1%
2025-08-18484,8343,3641,706,45228.4%
2025-08-15572,49801,631,52835.1%
2025-08-14556,83410,8191,480,83137.6%
2025-08-13679,8178432,318,34529.3%
2025-08-12380,0177,5621,317,59828.8%
2025-08-11430,0035,3761,522,23328.2%
2025-08-08468,95010,9831,686,08427.8%
2025-08-07421,78418,6141,650,96625.5%
2025-08-061,253,54830,6663,221,80438.9%
2025-08-052,037,55979,3136,276,53332.5%
2025-08-04628,20115,3121,926,12032.6%
2025-08-01798,74302,062,17838.7%
2025-07-31643,69018,6441,783,99036.1%
2025-07-30557,5172001,728,16832.3%
2025-07-29430,2214,9871,159,62937.1%
2025-07-28631,58919,8201,661,56838.0%
2025-07-25385,53301,615,63323.9%
2025-07-24356,85328,2031,105,68332.3%
2025-07-23326,12101,262,77525.8%
2025-07-22262,6930951,20727.6%
2025-07-21767,9666,5961,891,55240.6%
2025-07-18509,8871811,254,81740.6%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.